Kiffik Biomedical
Kiffik Biomedical is a Miami-based molecular diagnostics company that has developed the proprietary K-EXP™ platform for non-invasive access to Interstitial Fluid (ISF), enabling earlier biomarker detection and longitudinal monitoring for pharmaceutical, diagnostic, medical device, beauty, animal health, and research organizations.
- Company typePrivate
- Founded2018
- HeadquartersProvidence, United States
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
What Kiffik Biomedical does
Kiffik Biomedical Inc. is a Miami-based, privately held molecular infrastructure company (Delaware corporation, founded 2018) that has developed the K-EXP™ platform — a proprietary technology enabling controlled, non-invasive access to Interstitial Fluid (ISF) for repeat biological measurement. ISF is the molecular environment surrounding living cells, and Kiffik's central claim is that biomarkers measured in ISF provide earlier biological visibility than those captured in blood after systemic circulation. Platform evaluations report that 25%+ of biomarkers observed in ISF datasets were not detected in matched plasma samples, with elevated stability in select ISF samples relative to plasma.
The K-EXP™ platform supports a range of applications spanning biomarker discovery, longitudinal monitoring, therapeutic response evaluation, PK/PD measurement, and dynamic physiology tracking. It is positioned for use across early discovery, clinical development, and real-world biology, with stated validation in oncology, neurology, and cardiometabolic disease, alongside adjacent applications in dermatology, cardiology, stress physiology, recovery, inflammatory signaling, and performance monitoring. K-EXP is explicitly labeled investigational use only and is not FDA cleared.
Kiffik generates revenue through platform licensing, research partnerships, and strategic alliances rather than direct product sales. Its customer base is enterprise-oriented and segmented across pharmaceutical and biotech research organizations, clinical development teams, medical device and diagnostic companies, beauty and animal health organizations, and academic/research institutions. The company distributes globally through partnerships, with a recently announced (March 2026) alliance with HekaBio K.K. covering Japan and the broader Asia-Pacific region. Go-to-market is primarily via direct outreach and a website contact form targeting investors, partners, providers, researchers, and consumers — consistent with a business-development-led enterprise sales motion. The company closed an oversubscribed Series A in December 2025 to fund clinical program expansion, manufacturing scale-up, and regulatory milestones.
Kiffik Biomedical firmographics
Firmographics- Name
- Kiffik Biomedical
- Legal name
- Kiffik Biomedical Inc.
- Website
- https://kiffik.com
- Company type
- Private
- Founded year
- 2018
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Kiffik Biomedical is a Miami-based molecular diagnostics company that has developed the proprietary K-EXP™ platform for non-invasive access to Interstitial Fluid (ISF), enabling earlier biomarker detection and longitudinal monitoring for pharmaceutical, diagnostic, medical device, beauty, animal health, and research organizations.
- Ownership category
- akta.pro rank
Kiffik Biomedical industry classification
Industry- Product category
- Molecular Diagnostics Platform
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), Medical and Diagnostic Laboratories (62151)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835), Services-Commercial Physical & Biological Research (8731), Services-Medical Laboratories (8071)
- akta.pro primary industry
- Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity) (HLAGAAAD)
- akta.pro secondary industries
- Bioanalytical & PK/PD Sample Analysis (Trial Support) (HLAGAEAG), Liquid Biopsy Biomarkers (ctDNA/ctRNA/CTCs/exosomes) (HLAAAMAH), Molecular & Genetic Testing (PCR/NGS/qPCR) (HLAGADAF)
Keywords
Where Kiffik Biomedical is headquartered
LocationHeadquarters
- HQ city
- Providence
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Kiffik Biomedical business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales
Revenue model
- Platform Licensing and Partnership Deals: KIFFIK enables access to interstitial fluid for pharmaceutical, diagnostic, medical device, beauty, animal health, and research organizations. Revenue appears to be generated through platform licensing, research partnerships, and strategic alliances. The company operates globally through partnerships across research, clinical, and industrial domains.
Go-to-market motion2 records
Distribution channels1 record
Marketing channels1 record
Kiffik Biomedical product offering
Product offeringCore offering
Kiffik Biomedical develops the K-EXP™ platform, a proprietary molecular measurement technology that enables controlled, non-invasive access to Interstitial Fluid (ISF) for repeat biological measurement. The platform supports biomarker discovery, longitudinal monitoring, therapeutic response evaluation, PK/PD measurement, and dynamic physiology tracking across applications spanning early discovery, clinical development, and real-world biological monitoring in oncology, cardiology, neurology, and dermatology. The platform is offered to pharmaceutical, diagnostic, medical device, beauty, animal health, and research organizations through licensing, research partnerships, and strategic alliances.
Product overview
KIFFIK Biomedical offers a single unified product: the K-EXP™ platform. This core platform enables direct, non-invasive access to interstitial fluid (ISF) for molecular diagnostics and biomarker measurement, supporting applications across early discovery, clinical development, and real-world biological monitoring. The platform is designed for use across oncology, cardiology, neurology, and dermatology.
Differentiator
Problem solved
Functional benefit
Brands
- K-EXP: Real-time molecular diagnostics platform enabling controlled, non-invasive access to Interstitial Fluid (ISF) for repeat biological measurement. Supports biomarker discovery, longitudinal monitoring, therapeutic response evaluation, PK/PD measurement, and dynamic physiology tracking.
Products and services
- K-EXP™ Platform A proprietary real-time molecular diagnostics platform that enables controlled, non-invasive access to Interstitial Fluid (ISF) for repeat biological measurement. Supports biomarker discovery, longitudinal monitoring, therapeutic response evaluation, PK/PD measurement, and dynamic physiology tracking across oncology, cardiology, neurology, and dermatology applications. Offered to pharmaceutical, diagnostic, medical device, beauty, animal health, and research organizations through licensing and partnerships. KIFFIK EXP is not FDA cleared and is for investigational use only.
Quantifiable outcome
- 25%+ biomarkers observed in ISF datasets not detected in matched plasma
- +1 more outcomes
Companies that use Kiffik Biomedical
Customer profileSegments5 records
Ideal customer profiles4 records
Kiffik Biomedical technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Kiffik Biomedical partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- HekaBio K.K.coreStrategic alliance to expand K-EXP interstitial fluid (ISF) molecular measurement platform across Japan and broader Asia-Pacific region. HekaBio will support KIFFIK's regulatory strategy in Japan, serve as a local strategic advisor, and assist in establishing clinical and commercial partnerships in Japan and Korea. The K-EXP platform enables direct access to interstitial fluid for biomarker detection across oncology, cardiology, neurology, and dermatology applications.
Scale indicators4 records
Recent moves5 records
Expansion highlights6 records
Kiffik Biomedical competitors and assessment
Company assessmentDirect peers
- Profusa: Profusa develops injectable, injectable hydrogel-based biosensors that continuously monitor multiple analytes in interstitial fluid. It is the most direct competitor to Kiffik's K-EXP, working in the same ISF biofluid, same continuous-monitoring paradigm, and same multi-analyte biomarker positioning.
- Biolinq: Biolinq is developing intradermal biosensor patches that measure multiple analytes in interstitial fluid. Like Kiffik, Biolinq targets continuous, real-time, multi-biomarker monitoring from a minimally invasive skin-access platform, putting it in the same product category and customer use cases.
Broad incumbents
- Dexcom: Dexcom is the dominant continuous glucose monitor company, with sensor technology that reads glucose from interstitial fluid. While Dexcom is glucose-only today, its scale, regulatory infrastructure, and stated multi-analyte ambitions make it the most material incumbent competing for the ISF molecular-monitoring future Kiffik is targeting.
- Abbott Diabetes Care (FreeStyle Libre): Abbott's FreeStyle Libre franchise is the global volume leader in ISF-based continuous glucose sensing, with hundreds of millions of sensors shipped. Abbott is also investing in multi-analyte ISF sensing, putting it in direct conceptual competition with Kiffik's K-EXP at a much larger scale.
- Senseonics: Senseonics markets Eversense, the only FDA-approved implantable continuous glucose monitor that sits in interstitial fluid for up to six months. It validates the ISF long-duration monitoring concept that underpins Kiffik's platform, while competing for the same clinical/regulatory lane.
- Medtronic: Medtronic is a major ISF continuous glucose monitoring incumbent through its diabetes business and is investing in broader continuous sensing. Its global sales force and hospital-channel relationships set a high bar for any emerging ISF platform company, including Kiffik.
- Charles River Laboratories: Charles River Laboratories is a major preclinical and bioanalytical CRO that offers PK/PD, biomarker, and immunogenicity services — the same enterprise services that Kiffik is selling into pharma and biotech. It is a broad incumbent alternative for the same pharma/biotech budget dollars Kiffik targets.
- IQVIA: IQVIA is a global clinical and bioanalytical CRO that provides PK/PD, biomarker assay, and clinical-trial-support services. It competes with Kiffik for the same pharma clinical development and translational biomarker budgets, albeit through a vastly broader service portfolio.
Emerging players
- Epicore Biosystems: Epicore Biosystems develops sweat-based wearable biosensors for hydration, biomarkers, and metabolic monitoring. It is an emerging alternative-biofluid competitor addressing adjacent continuous molecular monitoring use cases that overlap with Kiffik's longitudinal biology tracking ambitions.
Others
- Quanterix: Quanterix provides ultra-sensitive single-molecule biomarker detection (Simoa) used in clinical research and pharma biomarker programs. While not an ISF platform, it is an enabling/competing biomarker-measurement technology that pharma customers may choose over Kiffik's K-EXP for ultra-sensitive protein biomarker discovery.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
Kiffik Biomedical social profiles
Digital presenceKiffik Biomedical financial estimates
Financial estimateRevenue estimate
Valuation estimate
Kiffik Biomedical leadership team
Management profileNumber of profiles
Profiles3 records
Kiffik Biomedical funding detail
Funding detailFunding overview
Funding rounds3 records
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Kiffik Biomedical M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Kiffik Biomedical
What does Kiffik Biomedical do?
Kiffik Biomedical develops the K-EXP™ platform, a proprietary molecular measurement technology that enables controlled, non-invasive access to Interstitial Fluid (ISF) for repeat biological measurement. The platform supports biomarker discovery, longitudinal monitoring, therapeutic response evaluation, PK/PD measurement, and dynamic physiology tracking across applications spanning early discovery, clinical development, and real-world biological monitoring in oncology, cardiology, neurology, and dermatology. The platform is offered to pharmaceutical, diagnostic, medical device, beauty, animal health, and research organizations through licensing, research partnerships, and strategic alliances.
Is Kiffik Biomedical a public or private company?
Kiffik Biomedical is a private company. It is classified as venture growth investor backed and is currently operating.
When was Kiffik Biomedical founded?
Kiffik Biomedical was founded in 2018. It employs 11 to 50 people.
Where is Kiffik Biomedical based?
Kiffik Biomedical is headquartered in Providence, United States, in the North America region.
How does Kiffik Biomedical make money?
One revenue line is on record: platform Licensing and Partnership Deals.
Who are Kiffik Biomedical's main competitors?
Direct peers on record are Profusa and Biolinq. Broad incumbents are Dexcom, Abbott Diabetes Care (FreeStyle Libre), Senseonics, Medtronic, Charles River Laboratories and IQVIA. Epicore Biosystems is listed as an emerging player. Quanterix is listed as an others.
Does Kiffik Biomedical have an API?
No public API is recorded for Kiffik Biomedical.
What industry is Kiffik Biomedical in?
Kiffik Biomedical's product category is Molecular Diagnostics Platform. Its primary akta.pro industry code is HLAGAAAD, Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity), with a secondary code of HLAGAEAG, Bioanalytical & PK/PD Sample Analysis (Trial Support). Its NAICS code is 541714 and its SIC code is 2835.